topics amgen-v-sanofi 
IP Watchdog
JANUARY 9, 2024
Patent and Trademark Office (USPTO) published guidelines for examiners today on the topic of enablement in light of the Supreme Court’s May 2023 decision in Amgen v.
Patently-O
NOVEMBER 6, 2022
On Friday, the Supreme Court granted certiorari on two petitions raising intellectual property issues, including the closely-watched enablement case Amgen v. The other case is a Abitron Austria GmbH v. Over the past few years, the Federal Circuit has issued a series of enablement decisions, including Amgen v.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Patently-O
SEPTEMBER 26, 2022
Topics: Enablement / Written Description (All three are biotech / pharma): 3 Cases; Infringement (FDA Labeling): 1 Case; Anticipation (On Sale Bar): 1 Case; Double Patenting (Still the law?) : 1 Case; Procedure / Standing: 6 Cases; Eligibility ( AmAxle Redux): 3 Cases; and. Randomness (don’t bother with these): 2 Cases. 4th 1013 (Fed.
Patently-O
FEBRUARY 24, 2022
20-891 (CVSG requested May 3, 2021); Res Judicata and the Patent-Specific Kessler Doctrine : PersonalWeb Technologies, LLC v. 20-1394 (CVSG requested October 4, 2021); Undermining Jury Decisions : Olaf Sööt Design, LLC v. Standing : The most recent CVSG is in Apple v. ” Eligibility : American Axle v. Patreon, Inc.,
LexBlog IP
AUGUST 28, 2023
On appeal, the Federal Circuit affirmed, citing the Supreme Court’s precedent regarding enablement in the recent Amgen Inc. at *5 (citing Amgen , 143 S. Realtime Data v. This topic was recently previewed in Realtime Data v. This topic was recently previewed in Realtime Data v. ” Id.
The IPKat
DECEMBER 22, 2023
G2/21 and the mysteries of plausibility The topic that this Kat has spent the most electronic ink on this year is undoubtedly G 2/21. After a flurry of decisions at the start of the year , the Boards of Appeal have gone rather silent on the topic of ViCo oral proceedings. This is one to watch for 2024.
Patently-O
NOVEMBER 11, 2022
As reported in posts by Dennis and Jason , the Supreme Court recently granted certiorari in Amgen v. Sanofi , marking the first time that the Court has taken up patent law’s enablement requirement since enactment of the Patent Act of 1952. A few days later, on November 7, the Supreme Court denied certiorari in Juno v.
Expert insights. Personalized for you.
114 
Let's personalize your content